A detailed history of Caxton Corp transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Caxton Corp holds 43,465 shares of CMPX stock, worth $59,547. This represents 0.34% of its overall portfolio holdings.

Number of Shares
43,465
Previous 43,465 -0.0%
Holding current value
$59,547
Previous $43,000 83.72%
% of portfolio
0.34%
Previous 0.23%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$1.4 - $1.98 $60,631 - $85,749
-43,308 Reduced 49.91%
43,465 $67,000
Q3 2023

Nov 14, 2023

BUY
$1.87 - $3.25 $80,984 - $140,747
43,307 Added 99.63%
86,773 $170,000
Q2 2023

Aug 14, 2023

SELL
$2.64 - $3.48 $444,243 - $585,593
-168,274 Reduced 79.47%
43,466 $138,000
Q1 2023

May 15, 2023

BUY
$3.14 - $5.48 $1,824 - $3,183
581 Added 0.28%
211,740 $692,000
Q4 2022

Feb 14, 2023

BUY
$2.55 - $5.41 $538,455 - $1.14 Million
211,159 New
211,159 $1.06 Million

Others Institutions Holding CMPX

About Compass Therapeutics, Inc.


  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $139M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track This Portfolio

Track Caxton Corp Portfolio

Follow Caxton Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Corp with notifications on news.